AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year ...

AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

Intensive chemotherapy improved survival in patients with accelerated and blast phase myeloproliferative neoplasms, with ...

This exemption stands as a notable advantage for the company’s cancer therapy drug, Venclexta, potentially preserving its competitive positioning and pricing dynamics in a challenging environment.

The submission is based on the positive results from the Phase 3 AMPLIFY trial. The combination regimen of VENCLEXTA and acalabrutinib improved progression-free survival (PFS) compared to standard ...

AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting chronic lymphocytic leukemia, which accompanies positive Phase 3 trial ...

AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting chronic lymphocytic leukemia, which accompanies positive Phase 3 trial outcomes.

About VENCLEXTA® (venetoclax) VENCLEXTA (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein.

VENCLEXTA and other medicines may affect each other causing serious side effects. Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.

About VENCLEXTA® (venetoclax) VENCLEXTA (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents ...

"This FDA submission marks a milestone for CLL treatment with the potential approval for the first oral combination regimen of VENCLEXTA and acalabrutinib for previously untreated patients with ...